TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16652380
Drug: 8‐week program
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8‐week program of clinic‐based or self‐administered behavioral training
Study: 10418181
Drug: Prefilled, disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefilled, disposable insulin pen injector (Novolet)
Study: 1691403
Drug: Quinapril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (10-40 mg/day, up to 80 mg/day)
Study: 2650581
Drug: Quinapril (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (once daily)
Study: 6271384
Drug: Concurrent chemotherapy‐irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy‐irradiation (CT‐RT)
Study: 6271384
Drug: Three‐week course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three‐week course of concurrent CT‐RT
Study: 10922131
Drug: Concurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent therapy
Study: 6271384
Drug: Sequential CT‐RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential CT‐RT
Study: 31655841
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (K Laser Cube 3)
Study: 21563042
Drug: Diclofenac epolamine
Normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac epolamine topical patch 1.3%
Study: 18474882
Drug: Decreased antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decreased antibiotic prescribing
Study: 18474882
Drug: Knowledge, attitudes,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge, attitudes, or behaviors favoring judicious antibiotic use
Study: 18474882
Drug: Concern about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concern about antibiotic resistance
Study: 8804327
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered iron for 6 months
Study: 6229429
Drug: Isotretinoin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 1.0 mg/kg
Study: 6229429
Drug: Isotretinoin 0.5
Normalized name: isotretinoin 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 0.5 mg/kg
Study: 29288190
Drug: Organ-saving treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Organ-saving treatment using long-course concurrent chemoradiation
Study: 19756664
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of etanercept and methotrexate (MTX)
Study: 15449975
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg/day for 6 weeks, then either maintained or increased to 8 mg/day based on BP response.
Study: 15449975
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg/day for 6 weeks (group II).
Study: 15449975
Drug: Perindopril monotherapy.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril monotherapy.
Study: 15449975
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg/day for group II patients.
Study: 15449975
Drug: Perindopril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril monotherapy in hypertensive diabetic patients.
Study: 15449975
Drug: Perindopril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril treatment in very elderly patients (>75 years).
Study: 15449975
Drug: Perindopril treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril treatment.
Study: 9331117
Drug: Paclitaxel 225
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 225 mg/m2 plus carboplatin (AUC 6)
Study: 9164208
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2
Study: 8435379
Drug: Torasemide 100
Normalized name: Torasemide 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 100 mg intravenous dose in patients with moderate renal insufficiency
Study: 8435379
Drug: Torasemide 200
Normalized name: torsemide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide 200 mg intravenous dose in patients with severe renal insufficiency
Study: 8435379
Drug: Torasemide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (various doses)
Study: 24497599
Drug: Polyhexanide solution
Normalized name: Polyhexanide
DrugBank: Polihexanide (DB12277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyhexanide solution
Study: 18374544
Drug: Aripiprazole (ARI)
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole (ARI) 10-30 mg/day
Study: 12814905
Drug: Ondansetron treatment
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron treatment (1, 4, and 16 micro g/kg twice daily)
Study: 24984823
Drug: Magnesium supplements
Normalized name: Magnesium supplements, alimentary tract and metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplements (8.1mmol of magnesium-pidolate, administered twice a day)
Study: 11815760
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (1 mg/kg, 1 dose)
Study: 6161451
Drug: Solcoseryl gel
Normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solcoseryl gel
Study: 6353619
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray (200 micrograms, twice daily for 4 weeks)
Study: 22579722
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid tablet (∼1,000 μg)
Study: 22579722
Drug: Multivitamin softgel
Normalized name: Complete Formulation Multivitamin Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin softgel capsule (∼1,000 μg)
Study: 16163525
Drug: Alcohol (0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.65 g/kg) after prior task experience with visual degradation
Study: 10545590
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (2 x 10^10 colony-forming units in capsules given twice daily during antimicrobial treatment)
Study: 7570411
Drug: Cotrimoxazole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole (960 mg twice daily)
Study: 7570411
Drug: Amoxicillin, Cotrimoxazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, Cotrimoxazole, or Placebo with oral corticosteroids
Study: 7570411
Drug: Amoxicillin, Cotrimoxazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, Cotrimoxazole, or Placebo
Study: 6985560
Drug: bezafibrate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (3 x 200 mg/d for 8 weeks)
Study: 6985560
Drug: clofibrate (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: clofibrate (3 x 500 mg/d for 8 weeks)
Study: 21173180
Drug: Miconazole oral
Normalized name: miconazole Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole oral gel (85 mg thrice daily)
Study: 19025522
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml (18 mg) hypobaric 0.6% lidocaine
Study: 19025522
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml (24 mg) hypobaric 0.6% lidocaine
Study: 23766519
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol (D₃) 600,000 IU
Study: 23766519
Drug: Oral ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ergocalciferol (D₂) 600,000 IU
Study: 23766519
Drug: Intramuscular cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular cholecalciferol (D₃) 600,000 IU
Study: 23766519
Drug: Intramuscular ergocalciferol
Normalized name: Ergocalciferol
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ergocalciferol (D₂) 600,000 IU
Study: 18405151
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (routine western methods including dehydration, brain-protection, anti-platelet agglutination, improving circulation, and expectant treatment)
Study: 11590492
Drug: Treatment 3
Normalized name: Canesten Clotrimazole Thrush Treatment 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 3 (didanosine, indinavir, and HU 500-1,000 mg/day)
Study: 11590492
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 (two nucleosides plus a protease inhibitor)
Study: 10868720
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2
Study: 1534642
Drug: Sustained-release nicardipine
Normalized name: nicardipine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nicardipine
Study: 31449090
Drug: Enhanced testing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced testing, linkage to care, and ARV treatment in 15 intervention villages.
Study: 26632428
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg melatonin (Melaxen(TM)) daily at 22:30 h for two weeks
Study: 24958736
Drug: UFT/LV (UFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT/LV (UFT 300 mg m(‐2) day(‐1), LV 75 mg/day on days 1-28 every 5 weeks)
Study: 24958736
Drug: 5‐FU/l‐LV (5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU/l‐LV (5‐FU 500 mg/m(2), l‐LV 250 mg/m(2) on days 1, 8, 15, 22, 29, 36 every 8 weeks)
Study: 24958736
Drug: 5‐FU/l‐LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU/l‐LV
Study: 17825800
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75-300 mg/day)
Study: 11488362
Drug: Fluoxetine (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20-60 mg/day)
Study: 17825800
Drug: Fluoxetine (continuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (continuation phase)
Study: 16362597
Drug: Terazosin 10
Normalized name: terazosin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin 10 mg after one month for group 2 and those with improvement or ineffectiveness from 5 mg
Study: 10080319
Drug: Implant-tissue-supported mandibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-tissue-supported mandibular overdenture on two IMZ implants (IMZ)
Study: 1539851
Drug: Heparin 200
Normalized name: HEPARIN 2000 UNIT/ML LOCK FLUSH SYR 3ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 200 U/kg and additional heparin as needed to maintain ACT > 400 s (group A, n = 30)
Study: 1539851
Drug: Heparin 400
Normalized name: heparin 40000 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 400 U/kg and additional heparin as needed to maintain whole blood heparin concentration > 4.0 U/ml (group H, n = 33)
Study: 27098551
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (PO-D)
Study: 27098551
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (IV-D)
Study: 20218793
Drug: Usual starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Usual starting dose of SSRIs (10 mg escitalopram; 20 mg fluoxetine, paroxetine, citalopram; 50 mg sertraline and fluvoxamine)
Study: 20218793
Drug: Higher starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher starting doses of SSRIs
Study: 20218793
Drug: Usual starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Usual starting dose of SSRIs
Study: 18767581
Drug: Turtle probing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Turtle probing the cave needling method (acupuncture therapy), treated once a day for two weeks.
Study: 18767581
Drug: Motilium (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motilium (10 mg oral administration, thrice daily, 30 minutes before meals, for two weeks).
Study: 15982149
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (present-centered therapy; PCT)
Study: 9737828
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg lubeluzole
Study: 9737828
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg lubeluzole
Study: 9737828
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lubeluzole
Study: 9737828
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of lubeluzole (5, 10, 15 mg)
Study: 9737828
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of lubeluzole
Study: 30312163
Drug: Complementary Spiritist
Normalized name: TURPENTINE SPIRITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary Spiritist Therapy (3 days, 10 mins per day/session) alongside conventional treatment
Study: 27616732
Drug: 7% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% maltodextrin solution (CHO)
Study: 27616732
Drug: 14% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14% maltodextrin solution (CHO)
Study: 24103519
Drug: Oleaginous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleaginous extract of kale (50 mL providing 10 mg lutein and 3 mg zeaxanthin per day)
Study: 14519051
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and calcium-channel blockers
Study: 29097499
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose lenalidomide (n=15)
Study: 29097499
Drug: Sequential azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential azacitidine and lenalidomide (n=39)
Study: 27655756
Drug: Low egg
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low egg (LE) - 75 g cooked egg
Study: 20799930
Drug: Group Art
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Art Therapy plus standard care
Study: 12480610
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 microg twice a day plus montelukast 10 mg at night for 8 weeks
Study: 10585054
Drug: Heparin‐bonded circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐bonded circuit with no albumin preprime
Study: 10585054
Drug: Heparin‐bonded circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐bonded circuit with albumin preprime
Study: 30759035
Drug: Aspirin 20
Normalized name: aspirin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 20 mg BD (12-hourly)
Study: 21226576
Drug: Amoxicillin‐clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanate
Study: 18642636
Drug: Median Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Median Nerve Stimulation (MNS) therapy
Study: 13679496
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks (Group A)
Study: 13679496
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg daily for 8 weeks (Group B)
Study: 10735395
Drug: Ciprofloxacin, 500
Normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg twice per day for 7 days (n = 128)
Study: 10735395
Drug: Trimethoprim-sulfamethoxazole, 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole, 160/800 mg twice per day for 14 days (n = 127)
Study: 1420504
Drug: Low-dose cytarabine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cytarabine (LDAC) 10 mg/m2 subcutaneously BID
Study: 28145050
Drug: CYP2B6 516
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2B6 516 G/G genotype
Study: 16505299
Drug: Defined over-ground
Normalized name: Turmeric,ground
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defined over-ground mobility therapy (CONT)
Study: 16505299
Drug: Body weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight support on a treadmill (BWSTT) and Defined over-ground mobility therapy (CONT)
Study: 12620436
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (newly initiated estrogen patch)
Study: 12620436
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal estrogen therapy
Study: 10710064
Drug: Ferumoxil (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxil (900 ml)
Study: 1540019
Drug: Cod liver
Normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod liver oil (10 ml daily)
Study: 3457524
Drug: Aspirin (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (650 mg four times daily)
Study: 18625629
Drug: COBRA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA treatment comprising sulfasalazine, methotrexate and high‐dose step‐down prednisolone, intensified by adding hydroxychloroquine and continued low‐dose prednisolone
Study: 12679450
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone (up to 45 mg for 77% of patients)
Study: 12679450
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg metformin (up to 2550 mg for 73% of patients)
Study: 12679450
Drug: 850 mg
Normalized name: bran 850 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 850 mg metformin
Study: 8770436
Drug: Self-care manual
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-care manual (part of the sequential treatment).
Study: 1593057
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg twice daily for 6 months
Study: 6323667
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic therapy (polymyxin-bacitracin ophthalmic ointment) applied four times a day for 7 days
Study: 6323667
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic therapy (polymyxin-bacitracin ophthalmic ointment)
Study: 31420274
Drug: Uric acid
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uric acid levels in the 3rd tertile (≥327 μmol/L)
Study: 31420274
Drug: High uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High uric acid levels (≥327 μmol/L)
Study: 27734491
Drug: Humidified oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidified oxygen at 60 l.min‐1 via nasal prongs (OptiflowTM) with the mouth open
Study: 27734491
Drug: Face mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face mask oxygenation at 10 l.min‐1
Study: 27734491
Drug: Humidified oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humidified oxygen at 60 l.min‐1 via nasal prongs (OptiflowTM) with the mouth closed
Study: 24670704
Drug: Treatment-induced decrease
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-induced decrease in CXCL10 levels in patients with 'insufficient' and 'deficient' vitamin D levels.
Study: 12014907
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotic prophylaxis)
Study: 30883233
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical agent
Study: 29156909
Drug: Palliative radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiotherapy (RT) with a single 8 Gy dose
Study: 25428176
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 0.5% (4 drops daily)
Study: 17578316
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI) in cooperation with chemotherapy (CAF protocol)
Study: 17578316
Drug: Chemotherapy (CAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CAF protocol) alone
Study: 10874
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate feedback during treatment
Study: 21114478
Drug: Isotretinoin at
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 24 weeks (group A)
Study: 21114478
Drug: Isotretinoin at
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin at 0·25‐0·4 mg kg⁻¹ daily for 24 weeks (group B)
Study: 21114478
Drug: Isotretinoin at
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 1 week out of every 4 weeks for 6 weeks (group C)
Study: 21114478
Drug: Isotretinoin at
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin at 0·25‐0·4 mg kg⁻¹ daily (group B)
Study: 21114478
Drug: Isotretinoin at
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily (group A)
Study: 21114478
Drug: Isotretinoin at
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin at 0·5‐0·7 mg kg⁻¹ daily for 1 week out of every 4 weeks (group C)